EUCTR2008-003283-20-DK进行中（未招募）不适用
A single arm, open-label, phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast cancer - HAX
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years.
- •2. Histologically or cytologically confirmed breast adenocarcinoma with measurable (per RECIST), locally recurrent or metastatic lesions.
- •3. Candidates for capecitabine-based chemotherapy. Locally advanced disease must not be amenable to resection with curative intent.
- •4. Documented HER2 positive disease (HER2 overexpression indicated by IHC 3+ and/or FISH + and/or chromogenic in situ hybridization (CISH) + of the primary tumor or a metastasis).
- •5. Documented ER/PgR status (positive or negative).
- •6. ECOG Performance Status = 2.
- •7. Able and willing to comply with the protocol.
- •8. Written and signed informed consent prior to beginning study-specific procedures showing the patient’s awareness and willingness to participate in the trial and comply with its proceedings and with the understanding that the patient has the right to withdraw from the study at any time without prejudice. (Note: the informed consent document must be approved by the institution’s Independent Ethics Committee).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 77
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 11
排除标准
- •1. Previous treatment for locally advanced or mBC other than hormone therapy or radiotherapy. Anti-epidermal growth factor receptor or anti-HER2 agents or vaccines and cytotoxic chemotherapies for locally recurrent or mBC are not allowed. Patients must have fully recovered from side effects of any prior radiotherapy.
- •2. Any prior neoadjuvant or adjuvant treatment with anthracyclines completed less than 6 months prior to enrolment. The max. cumulative dose received must not have exceeded 360 mg/sqm for doxorubicin or 720 mg/sqm for epirubicin.
- •3. Chronic daily treatment with corticosteroids and/or with aspirin or clopidogrel.
- •4. Requirement for concurrent use of the antiviral agent sorivudine, or chemically related analogues, such as brivudine.
- •5. Minor surgical procedures, within 24 hours prior to enrolment.
- •6. Current or recent (within the 30 days prior to starting study treatment) treatment with another investigational drug or participation in another investigational study.
- •7. Inadequate bone marrow function, liver function and or renal function
- •8. Patients not receiving anticoagulant medication who have an International Normalized Ratio (INR) > 1.5 or an activated partial thromboplastin time (aPTT) > 1.5 x ULN within 7 days prior to enrollment.
- •Note: Patients receiving full dose oral or parenteral anticoagulants may be included as long as anticoagulant dosing has been stable for at least two weeks prior to study entry and the appropriate coagulation monitoring tests are within therapeutic limits.
- •9. Other primary malignancy (including primary brain tumors) within the last 5 years prior to enrolment, except for adequately treated carcinoma in situ of the cervix, squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.
- •10. Dyspnea at rest due to complications of advanced malignancy (e.g. pulmonary metastases with lymphangitis) or any condition necessitating supportive oxygen therapy.
- •11. Evidence of CNS metastasis.
- •12. Evidence of spinal cord compression caused by metastases.
- •13. History or evidence upon physical/neurological examination of CNS disease unrelated to cancer (e.g. uncontrolled seizures) unless adequately treated with standard medical therapy.
- •14. Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to enrolment, or anticipation of the need for major surgery during the course of the study treatment.
- •15. Uncontrolled hypertension (systolic > 150 mm Hg and/or diastolic > 100 mm Hg) or clinically significant (i.e. active) cardiovascular disease
- •16. Baseline LVEF < 50% measured by either echocardiography or MUGA.
- •17. History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding.
- •18. History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months of enrolment.
- •19. Active infection requiring IV antibiotics at enrolment.
- •20. Serious non-healing wound, peptic ulcer, or bone fracture.
- •21. Clinically significant malabsorption syndrome, or inability to take oral medication.
- •22. Evidence of any other disease, metabolic or psychological dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect patient compliance with study routines, or place the patient at high risk from treatment related complications.
研究者
相似试验
进行中（未招募）
不适用
A single arm, open-label, phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast cancerHER2-positive locally recurrent or metastatic breast cancer.MedDRA version: 9.1Level: LLTClassification code 10027475Term: Metastatic breast cancerMedDRA version: 9.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerMedDRA version: 9.1Level: LLTClassification code 10006198Term: Breast cancer recurrentEUCTR2008-003283-20-SKF. Hoffmann-La Roche Ltd88
进行中（未招募）
不适用
A study of bevacizumab in combination with trastuzumab and capecitabine in patients with breast cancer that recurred at/near the same place as the original tumour or that spread to other non-adjacent tissuesHER2-positive locally recurrent or metastatic breast cancer.MedDRA version: 14.1Level: LLTClassification code 10027475Term: Metastatic breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10006198Term: Breast cancer recurrentSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: LLTClassification code 10065430Term: HER-2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-003283-20-SEF. Hoffmann-La Roche Ltd88
进行中（未招募）
不适用
A single arm, open-label, phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of patients with HER2-positive locally recurrent or metastatic breast cancerEUCTR2008-003283-20-FRF. Hoffmann-La Roche Ltd88
已完成
2 期
A multicenter, single-arm phase II trial of bevacizumab beyond initial progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in Advanced Colorectal Canceruntreated and unresectable metastatic colorectal cancerJPRN-UMIN000006818Chubu Clinical Oncology Group (CCOG)50
进行中（未招募）
不适用
Open-label, single-arm, phase II study of bevacizumab (AVASTIN®)in combination with low-dose interferon as first-line treatment ofnephrectomised patients with metastatic clear cell renal cell carcinoma - BEVLiEUCTR2007-006611-23-DEF. Hoffmann-La Roche Ltd140